Intravascular Chemical Sensors with Improved Biocompatiblity/Performance via Nitric Oxide Release

通过一氧化氮释放改善生物相容性/性能的血管内化学传感器

基本信息

  • 批准号:
    9525342
  • 负责人:
  • 金额:
    $ 39.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-21 至 2020-06-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT To date, efforts to develop clinically viable in vivo chemical sensors for real-time monitoring of blood gases, electrolytes, glucose, lactate, etc. in critically ill hospital patients have been stymied by inaccurate analytical results due to sensor biocompatibility problems (cell adhesion, thrombus formation, etc.) and a high risk of infection. Our research over the past 15 years has been to explore and optimize the chemistry required to fabricate in vivo chemical sensors that slowly release low levels of nitric oxide (NO). The local release of NO mimics the chemistry that occurs at the inner walls of all healthy blood vessels (NO production by endothelium) and by immune cells (macrophages, neutrophils) and is expected to greatly enhance the biocompatibility and bactericidal properties of the intravascular sensors. This will lead to improved analytical performance of the implanted sensors and less risk of infection. Indeed, results obtained with prior NIH support have clearly demonstrated that in situ release of NO significantly reduces surface thrombus formation and improves the in vivo analytical accuracy of intravascular oxygen and glucose sensors. Very recently, a completely new type of NO releasing polymer material (S-nitrosothiol (RSNO) impregnated catheter tubing) has been developed that possesses highly desirable long-term shelf stability, long-term NO release, ease of sterilization with ETO, and low toxicity. We now wish to utilize this simple and low cost NO release chemistry to implement a new phase of research that we anticipate will lead to translation of this technology to real-time sensor technology for the intensive care units (ICU) at the end of the proposed 4-year project period. Our primary goal will be to assess whether these new materials can be readily used to fabricate catheter type electrochemical sensors (for oxygen, glucose, and lactate) that exhibit greatly enhanced in vivo analytical performance (in pigs and sheep). In addition to NO release, we will also explore the potential advantages of combining the new RSNO- impregnation chemistry with immobilized CD47 on the surface of the sensors. CD47 is a potent anti- inflammatory/anti-platelet activation agent that binds to the SIRPα receptor on surfaces of many inflammatory cells, including platelets. Optimal NO release and combined NO release/CD47 modified sensors for monitoring oxygen (PO2), glucose, and lactate will first be evaluated side-by-side (vs. corresponding non-NO release controls) in vivo within arteries and veins of anesthetized pigs (over 24 h period). The most promising approach derived from this initial screening will then be tested in fully awake sheep over 10 d periods to prove the enhanced analytical performance resulting from the antithrombotic/antimicrobial properties of this new generation of implantable electrochemical sensors. The ability to reliably measure critical care analytes in blood continuously at a patient's bedside is the “holy grail” for biomedical sensor technology, and this goal can only be achieved when sensor performance is not compromised by biocompatibility and infection issues.
摘要 到目前为止,开发临床上可行的体内化学传感器用于实时监测血气的努力, 危重病人体内的电解质、葡萄糖、乳酸等因分析不准确而受阻。 结果由于传感器生物兼容性问题(细胞粘连、血栓形成等)并且有很高的风险 感染。我们在过去15年的研究一直在探索和优化所需的化学物质 制造体内化学传感器,缓慢释放低水平的一氧化氮(NO)。NO在当地的释放 模拟所有健康血管内壁发生的化学物质(内皮细胞不产生) 并通过免疫细胞(巨噬细胞、中性粒细胞),有望大大提高生物相容性和 血管内传感器的杀菌性能。这将导致改进分析性能 植入传感器,感染风险更低。事实上,在NIH之前的支持下获得的结果显然已经 研究表明,NO的原位释放显著减少了表面血栓的形成,并改善了动脉粥样硬化。 血管内氧气和葡萄糖传感器的活体分析准确性。最近,一种全新的类型 开发了一种释放NO的聚合物材料(S-亚硝硫醇浸渍导管管材)。 具有非常理想的长期货架稳定性,长期不释放,使用ETO易于灭菌,以及 低毒。我们现在希望利用这种简单和低成本的无释放化学物质来实现新的阶段 我们预期的研究将导致将这项技术转化为用于 在拟议的4年项目期结束时建立重症监护病房(ICU)。我们的主要目标将是评估 这些新材料是否可以容易地用来制造导管型电化学传感器(用于 氧、葡萄糖和乳酸),大大提高了活体分析性能(在猪和羊身上)。 除了NO释放,我们还将探索结合新的RSNO- 固定化CD47在传感器表面的浸渍化学。CD47是一种强大的抗肿瘤药物 炎症/抗血小板激活剂,与许多炎症性疾病表面的Sirpα受体结合 细胞,包括血小板。最佳的NO释放和组合的NO释放/CD47修饰传感器用于监测 将首先并排评估氧气(PO2)、葡萄糖和乳酸(与相应的不释放NO相比 对照)在体动、静脉内注射(24小时以上)。最有希望的 从这种初步筛选中得出的方法将在完全清醒的绵羊身上进行为期10天的测试,以证明 这一新的抗血栓/抗菌性能带来的分析性能增强 植入式电化学传感器的产生。能够可靠地测量危重护理分析物 持续在患者床边的血液是生物医学传感器技术的“圣杯”,这一目标可以 只有在传感器性能不受生物兼容性和感染问题影响的情况下才能实现。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK E MEYERHOFF其他文献

MARK E MEYERHOFF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK E MEYERHOFF', 18)}}的其他基金

Advanced Thromboresistant/Bactericidal Catheters via Electromodulated NO Release
通过电调节 NO 释放的先进抗血栓/杀菌导管
  • 批准号:
    9405609
  • 财政年份:
    2017
  • 资助金额:
    $ 39.47万
  • 项目类别:
Amperometric NO(g) Sensors with Improved Selectivity/Sensitivity for Biomedical Measurements
用于生物医学测量的具有更高选择性/灵敏度的电流型 NO(g) 传感器
  • 批准号:
    9068096
  • 财政年份:
    2015
  • 资助金额:
    $ 39.47万
  • 项目类别:
Amperometric NO(g) Sensors with Improved Selectivity/Sensitivity for Biomedical Measurements
用于生物医学测量的具有更高选择性/灵敏度的电流型 NO(g) 传感器
  • 批准号:
    8967508
  • 财政年份:
    2015
  • 资助金额:
    $ 39.47万
  • 项目类别:
Advanced Thromboresistant/Bactericidal Catheters via Electromodulated NO Release
通过电调节 NO 释放的先进抗血栓/杀菌导管
  • 批准号:
    8916211
  • 财政年份:
    2014
  • 资助金额:
    $ 39.47万
  • 项目类别:
Reducing Tunneled Dialysis Catheter Dysfunction through Nitric Oxide Release
通过释放一氧化氮减少隧道式透析导管功能障碍
  • 批准号:
    9188634
  • 财政年份:
    2013
  • 资助金额:
    $ 39.47万
  • 项目类别:
Reducing Tunneled Dialysis Catheter Dysfunction through Nitric Oxide Release
通过释放一氧化氮减少隧道式透析导管功能障碍
  • 批准号:
    8741962
  • 财政年份:
    2013
  • 资助金额:
    $ 39.47万
  • 项目类别:
Reducing Tunneled Dialysis Catheter Dysfunction through Nitric Oxide Release
通过释放一氧化氮减少隧道式透析导管功能障碍
  • 批准号:
    8638515
  • 财政年份:
    2013
  • 资助金额:
    $ 39.47万
  • 项目类别:
Thromboresistant Polymers Via Catalytic Generation of NO
通过催化生成 NO 的抗血栓聚合物
  • 批准号:
    7644722
  • 财政年份:
    2005
  • 资助金额:
    $ 39.47万
  • 项目类别:
Thromboresistant Polymers via Catalytic Generation of NO
通过催化生成 NO 的抗血栓聚合物
  • 批准号:
    7407496
  • 财政年份:
    2005
  • 资助金额:
    $ 39.47万
  • 项目类别:
Thromboresistant Polymers Via Catalytic Generation of NO
通过催化生成 NO 的抗血栓聚合物
  • 批准号:
    8241135
  • 财政年份:
    2005
  • 资助金额:
    $ 39.47万
  • 项目类别:

相似海外基金

Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
  • 批准号:
    23K07659
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
  • 批准号:
    23K15705
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
  • 批准号:
    23K19490
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
  • 批准号:
    10697567
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
  • 批准号:
    10727765
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
  • 批准号:
    23K08467
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
  • 批准号:
    493138
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
  • 批准号:
    23K13905
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
  • 批准号:
    2223225
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
    Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
  • 批准号:
    10651054
  • 财政年份:
    2023
  • 资助金额:
    $ 39.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了